

Protalix BioTherapeutics, Inc.

Form 8-K

October 28, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 28, 2008

**Protalix BioTherapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

|                                                      |                             |                                      |
|------------------------------------------------------|-----------------------------|--------------------------------------|
| Florida                                              | 000-27836                   | 65-0643773                           |
| (State or other<br>jurisdiction of<br>incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

**2 Snunit Street  
Science Park  
POB 455  
Carmiel, Israel 20100**  
(Address of principal executive offices) (Zip Code)

(Former Name or Former Address, if Changed Since Last Report)

Registrant's telephone number, including area code: +972-4-988-9488

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 7.01. Regulation FD Disclosure

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EX-99.1: PRESS RELEASE

---

**Table of Contents**

**Item 7.01. Regulation FD Disclosure**

On October 28, 2008, Protalix BioTherapeutics, Inc. (the Company) issued a press release announcing that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the 19th Annual Oppenheimer Healthcare Conference on Monday, November 3, 2008, at 4:00 PM EDT. The Company also announced that Dr. Aviezer will present at the Barclays Capital Small & Mid-Cap Healthcare Conference on Thursday, November 6, 2008, at 9:30 AM EDT. A copy of the press release is furnished as Exhibit 99.1 to this Report.

Audio webcasts of the presentations will be available on the Company's website at [www.protalix.com](http://www.protalix.com) under the events calendar section.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated October 28, 2008.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX BIOTHERAPEUTICS, INC.**

Date: October 28, 2008

By: /s/ David Aviezer

Name: David Aviezer, Ph.D.

Title: President and Chief Executive Officer

3